N2OFF loans $250K to MitoCareX; issues 650K shares to directors

Nexentis Technologies Inc.

Loaned $250,000 to MitoCareX Bio Ltd. at Israel Tax Authority rate + 3%, due in six months.
Loan guaranteed by L.I.A. Pure Capital Ltd. If MitoCareX becomes a subsidiary, outstanding amount deducted from future allocations.
Issued 650,000 common shares to directors under 2022 Share Incentive Plan on December 23, 2024.
Board and compensation committee recommended issuance; non-binding stockholder approval received November 13, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.